Pharma main Dr. Reddy’s Laboratories’ wholly owned step-down subsidiary Dr. Reddy’s Laboratories, Inc. has been named as a defendant in a complaint filed in a U.S. court docket associated to sale of name and generic cancer drug Revlimid, the second such in as many months.
“Dr. Reddy’s Laboratories, Inc. along with several other pharmaceutical companies was named as a defendant in a complaint filed on November 8 in the United States District Court for the District of New Jersey,” the mother or father firm mentioned in a inventory change submitting on Thursday.
It mentioned the complaint, filed by Intermountain Health, Inc., “asserts claims under Federal and State antitrust laws and other State laws alleging that the defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid through their respective settlements of patent litigation.”
Alleging that the “challenged agreements improperly delayed generic entry completely till 2022 after which improperly restricted generic competitors by 2026, the complaint has sought damages for purported overpayments and equitable aid.
Dr. Reddy’s mentioned the allegations against it lack benefit and the corporate will vigorously defend the litigation.
In October, the Hyderabad-headquartered drugmaker had in an analogous inventory change submitting mentioned the wholly owned, step-down subsidiary, with a number of different pharmaceutical firms, had been named as a defendant in a complaint – much like the most recent – filed by Mayo Clinic and Lifepoint Corporate Services over Revlimid in the United States District Court for the Northern District of California.
Earlier, in November 2022, Dr. Reddy’s Laboratories had mentioned it together with just a few different drugmakers had been named defendants in a complaint filed in the U.S. below the Federal and State antitrust legal guidelines over Revlimid. In December, Dr. Reddy’s mentioned all claims against the corporate in the anti-trust litigation had been dismissed.
